SS-31 50MG

Primary Target: Cardiolipin (CL) on the Inner Mitochondrial Membrane

SS-31 does NOT bind to a protein receptor. Instead, it binds directly to cardiolipin (CL) — an anionic phospholipid unique to the IMM that is critical for organizing the electron transport chain (ETC) into functional supercomplexes (respirasomes). The binding is driven by two forces:[1][2]

• Electrostatic: D-Arg and Lys (cationic residues) bind the anionic phosphate head groups of CL
• Hydrophobic: Dmt and Phe (aromatic residues) intercalate into the hydrophobic acyl chain region of CL
• Selectivity: SS-31 does NOT bind zwitterionic phospholipids (e.g., phosphatidylcholine, phosphatidylethanolamine) — purely selective for anionic CL

Downstream Cascade

Step	Mechanism	Functional Outcome
1. CL binding	High-affinity IMM localization (5,000×)	Prevents pathological CL/cytochrome c peroxidase activity[2]
2. Cyt c preservation	Stabilizes CL → preserves cyt c electron carrier function	Facilitates Complex III→IV electron transfer → ↑ATP synthesis[1]
3. Supercomplex assembly	Stabilizes ETC respirasomes	Optimizes oxidative phosphorylation coupling efficiency[5]
4. Cristae preservation	Optimizes IMM curvature	Prevents mitochondrial swelling and fragmentation[4]
5. mPTP inhibition	Prevents mitochondrial permeability transition pore opening	Reduces ischemia-reperfusion injury, apoptosis[6]
6. NF-κB inhibition	Prevents p65 nuclear translocation	Reduced pro-inflammatory cytokine production[7]
7. NLRP3 inhibition	Reduces inflammasome activation	↓ IL-1β, IL-18 production[7]
8. Nrf2/SIRT1/PGC-1α	HO-1 upregulation; mitochondrial biogenesis	Antioxidant gene expression; restored mitochondrial mass[5]
9. BDNF signaling	Enhances synapsin-1, PSD-95, p-CREB	Neuroprotection, cognitive function[8]

vs. Related Mitochondrial Compounds

Compound	Primary Target	Membrane Potential Dep.	Key Difference
SS-31 (elamipretide)	Cardiolipin (IMM)	No	Reaches severely dysfunctional mitochondria; no depolarization at high concentrations
MitoQ	Mitochondrial matrix	Yes (requires ΔΨm)	Depolarizes at high doses; cannot reach severely damaged mito
NAC (N-acetylcysteine)	Cytosolic GSH replenishment	No	Stoichiometric scavenging; not concentrated at ROS source
MOTS-c	Folate cycle / Nuclear ARE	No	Mitokine; targets nuclear gene regulation via AMPK/Nrf2 rather than direct ETC

Cardiolipin-Specific Membrane Lipid Targeting Profiling

A defining mechanistic feature investigated in the SS-31 research literature is the selectivity for anionic cardiolipin over zwitterionic phospholipids of the IMM. Surface-plasmon-resonance and isothermal-titration-calorimetry studies have characterized the binding architecture: the two cationic residues (D-Arg, Lys) form salt-bridges with cardiolipin's two phosphate head groups while the two aromatic residues (Dmt, Phe) intercalate between the four acyl chains, locking SS-31 onto the matrix-facing leaflet of the IMM where ETC supercomplexes assemble. No measurable interaction is observed with phosphatidylcholine, phosphatidylethanolamine, or phosphatidylserine model bilayers, providing a control set that lets investigators attribute mitochondrial readouts specifically to cardiolipin engagement rather than nonspecific membrane perturbation.[2]

Mitochondrial Quality-vs-Quantity Distinction Research

A second mechanistic theme that distinguishes SS-31 from biogenesis-driven research compounds is the quality-without-quantity profile. In aged-rodent skeletal-muscle and cardiac models, eight-week SS-31 exposure reverses ATP_max decline, normalizes O₂ consumption and electron-transport coupling efficiency, and restores cristae ultrastructure on transmission-electron-microscopy quantification — without measurable increases in mtDNA copy number, citrate-synthase activity, or PGC-1α-driven mitochondrial mass.[4] This improvement of existing mitochondria phenotype is mechanistically distinct from the biogenesis-driven mitochondrial expansion observed with MOTS-c or PGC-1α-axis interventions, and supplies investigators studying mitochondrial quality control with a tool that perturbs the cardiolipin-ETC axis without confounding biogenesis signals.[1]

SS-31/elamipretide has been investigated across 10+ indication categories, with particular depth in cardiovascular, renal, ophthalmic, and aging research:

1. Barth Syndrome (Genetically-Confirmed Cardiolipin Deficiency) — TAFAZZIN gene mutations → cardiolipin deficiency → mitochondrial dysfunction. FDA Accelerated Approval (Sept 2025) for Forzinity™ based on TAZPOWER OLE data: +96.1 m 6MWT improvement (p=0.003) over 168 weeks; improved muscle strength and LV stroke volume.[3][9]
2. Primary Mitochondrial Myopathy (PMM) — MMPOWER Phase 1/2 (n=36): IV 0.25 mg/kg/h × 5 days → +64.5 m 6MWT vs +20.4 m placebo (p=0.053), significant dose-dependent benefit (p=0.014). MMPOWER-3 Phase 3 (n=218): failed primary endpoints (6MWT -3.2 m, p=0.69); post-hoc benefit in nDNA replisome mutation subgroup.[10]
3. Heart Failure — Sabbah et al. (2016): dogs with microembolization HF — 0.5 mg/kg SC × 3 months; LVEF improved 30% → 36% (p<0.05); NT-proBNP decreased 774 pg/mL (p<0.001); ATP/ADP ratio 1.16 vs 0.38 control. PROGRESS-HF Phase 2 (n=71): 4 or 40 mg SC × 28 days; no significant LVESV change. Phase 1 (n=36): IV 0.25 mg/kg/h × 4h → significant LV volume reductions.[6][5]
4. Ischemia-Reperfusion Injury — Cardiac, renal, and cerebral I/R: ATP recovery, tissue protection, mPTP prevention; demonstrated in multiple rodent/large animal models.[11]
5. Age-Related Macular Degeneration (Dry AMD) — ReCLAIM-2 Phase 2: 40 mg SC daily; failed primary endpoints (VA, GA area); slowed ellipsoid zone degradation. ReNEW Phase 3 (NCT06373731): n=360 target, 40 mg SC daily × 96 weeks; ongoing.[12]
6. Renal Disease — ARAS Phase 2a (n=14): IV during angioplasty → renal blood flow 262 vs 202 mL/min (p=0.04); improved GFR. Diabetic nephropathy: podocyte and brush border protection in rodent models.[13]
7. Aging and Sarcopenia — Campbell et al. (2019): 26-month female C57BL/6 mice — 3 mg/kg/day SC × 8 weeks; treadmill endurance nearly doubled (p<0.05); reversed ATPmax decline; no increase in mitochondrial content (bioenergetic quality improvement, not quantity).[4]
8. Cardiovascular / Atherosclerosis — Plaque reduction, CD36 downregulation; 55% inhibition of advanced plaque development in ApoE⁻/⁻ mice with chronic SS-31 treatment.[7]
9. Neurodegenerative Disorders — Alzheimer's disease: Zhao et al. (2019) LPS cognitive impairment mice — 5 mg/kg IP; escape latency reduced (p<0.01); hippocampal TNF-α/IL-6 reduced (p<0.05). Parkinson's disease, ALS — crosses BBB (small, water-soluble, cationic).[8]
10. Glaucoma / Diabetic Retinopathy — Retinal ganglion cell preservation; mitochondrial ROS reduction in retinal neurons; topical ophthalmic formulation studied in LHON trial.[12]